Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells

Rong Nian Shen, Li Lu, Hal Broxmeyer, Homayoon Shidnia, Ned B. Hornback, Hal E. Broxmeyer

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Recombinant human (rhu) interleukin 2 (IL-2) was evaluated alone and in combination with local hyperthermia (LH) in mice inoculated s.c. with 5 × 105 Lewis lung carcinoma cells. Four treatment regimens were begun 6 days postinoculation at a time when the tumor had grown to approximately 8.0 mm in diameter. Treatments were: group 1, saline injected as control; group 2, LH; group 3, rhuIL-2; or group 4, LH combined with rhuIL-2. LH utilized hot water circulation by a Brann Thermomix 1420. The intratumor temperature was maintained at 43 ± 0.2°C for 30 min each on days 6 and 10 and rhuIL-2 was given s.c. at 5 × 104 units twice a day for 5 days. Thirty mice in each group were sacrificed 28 days after tumor inoculation. An additional 20 mice in each group were observed for survival time. The size of primary tumor and the number of lung metastases were reduced and the survival time was prolonged in mice treated by either LH or IL-2. However, a greater antitumor effect in Lewis lung carcinoma tumor-bearing mice was observed using IL-2 therapy combined with LH. Tumor growth was associated with increased splenic granulocyte-macrophage progenitor cells and an abnormal L3T4+/Lyt-2+ lymphocyte subset ratio (<1.0). Splenic granulocyte-macrophage progenitor cell numbers and the L3T4+/Lyt-2+ ratio returned to normal in the group treated with combination therapy, the best responder group. The L3T4+/Lyt-2+ ratio did not change in the groups treated with single therapy. These results suggest the efficacy and possible clinical relevance of combined therapy with rhuIL-2 and LH for certain metastatic tumors.

Original languageEnglish
Pages (from-to)5027-5030
Number of pages4
JournalCancer Research
Volume50
Issue number16
StatePublished - Aug 15 1990

Fingerprint

Lewis Lung Carcinoma
Induced Hyperthermia
Interleukin-2
Neoplasms
Granulocyte-Macrophage Progenitor Cells
Therapeutics
Survival
Lymphocyte Subsets
Cell Count
Neoplasm Metastasis
Lung
Temperature
Water
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Shen, R. N., Lu, L., Broxmeyer, H., Shidnia, H., Hornback, N. B., & Broxmeyer, H. E. (1990). Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells. Cancer Research, 50(16), 5027-5030.

Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells. / Shen, Rong Nian; Lu, Li; Broxmeyer, Hal; Shidnia, Homayoon; Hornback, Ned B.; Broxmeyer, Hal E.

In: Cancer Research, Vol. 50, No. 16, 15.08.1990, p. 5027-5030.

Research output: Contribution to journalArticle

Shen, RN, Lu, L, Broxmeyer, H, Shidnia, H, Hornback, NB & Broxmeyer, HE 1990, 'Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells', Cancer Research, vol. 50, no. 16, pp. 5027-5030.
Shen, Rong Nian ; Lu, Li ; Broxmeyer, Hal ; Shidnia, Homayoon ; Hornback, Ned B. ; Broxmeyer, Hal E. / Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells. In: Cancer Research. 1990 ; Vol. 50, No. 16. pp. 5027-5030.
@article{39c0c19cfc2041c89fcb202544e4450a,
title = "Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells",
abstract = "Recombinant human (rhu) interleukin 2 (IL-2) was evaluated alone and in combination with local hyperthermia (LH) in mice inoculated s.c. with 5 × 105 Lewis lung carcinoma cells. Four treatment regimens were begun 6 days postinoculation at a time when the tumor had grown to approximately 8.0 mm in diameter. Treatments were: group 1, saline injected as control; group 2, LH; group 3, rhuIL-2; or group 4, LH combined with rhuIL-2. LH utilized hot water circulation by a Brann Thermomix 1420. The intratumor temperature was maintained at 43 ± 0.2°C for 30 min each on days 6 and 10 and rhuIL-2 was given s.c. at 5 × 104 units twice a day for 5 days. Thirty mice in each group were sacrificed 28 days after tumor inoculation. An additional 20 mice in each group were observed for survival time. The size of primary tumor and the number of lung metastases were reduced and the survival time was prolonged in mice treated by either LH or IL-2. However, a greater antitumor effect in Lewis lung carcinoma tumor-bearing mice was observed using IL-2 therapy combined with LH. Tumor growth was associated with increased splenic granulocyte-macrophage progenitor cells and an abnormal L3T4+/Lyt-2+ lymphocyte subset ratio (<1.0). Splenic granulocyte-macrophage progenitor cell numbers and the L3T4+/Lyt-2+ ratio returned to normal in the group treated with combination therapy, the best responder group. The L3T4+/Lyt-2+ ratio did not change in the groups treated with single therapy. These results suggest the efficacy and possible clinical relevance of combined therapy with rhuIL-2 and LH for certain metastatic tumors.",
author = "Shen, {Rong Nian} and Li Lu and Hal Broxmeyer and Homayoon Shidnia and Hornback, {Ned B.} and Broxmeyer, {Hal E.}",
year = "1990",
month = "8",
day = "15",
language = "English",
volume = "50",
pages = "5027--5030",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells

AU - Shen, Rong Nian

AU - Lu, Li

AU - Broxmeyer, Hal

AU - Shidnia, Homayoon

AU - Hornback, Ned B.

AU - Broxmeyer, Hal E.

PY - 1990/8/15

Y1 - 1990/8/15

N2 - Recombinant human (rhu) interleukin 2 (IL-2) was evaluated alone and in combination with local hyperthermia (LH) in mice inoculated s.c. with 5 × 105 Lewis lung carcinoma cells. Four treatment regimens were begun 6 days postinoculation at a time when the tumor had grown to approximately 8.0 mm in diameter. Treatments were: group 1, saline injected as control; group 2, LH; group 3, rhuIL-2; or group 4, LH combined with rhuIL-2. LH utilized hot water circulation by a Brann Thermomix 1420. The intratumor temperature was maintained at 43 ± 0.2°C for 30 min each on days 6 and 10 and rhuIL-2 was given s.c. at 5 × 104 units twice a day for 5 days. Thirty mice in each group were sacrificed 28 days after tumor inoculation. An additional 20 mice in each group were observed for survival time. The size of primary tumor and the number of lung metastases were reduced and the survival time was prolonged in mice treated by either LH or IL-2. However, a greater antitumor effect in Lewis lung carcinoma tumor-bearing mice was observed using IL-2 therapy combined with LH. Tumor growth was associated with increased splenic granulocyte-macrophage progenitor cells and an abnormal L3T4+/Lyt-2+ lymphocyte subset ratio (<1.0). Splenic granulocyte-macrophage progenitor cell numbers and the L3T4+/Lyt-2+ ratio returned to normal in the group treated with combination therapy, the best responder group. The L3T4+/Lyt-2+ ratio did not change in the groups treated with single therapy. These results suggest the efficacy and possible clinical relevance of combined therapy with rhuIL-2 and LH for certain metastatic tumors.

AB - Recombinant human (rhu) interleukin 2 (IL-2) was evaluated alone and in combination with local hyperthermia (LH) in mice inoculated s.c. with 5 × 105 Lewis lung carcinoma cells. Four treatment regimens were begun 6 days postinoculation at a time when the tumor had grown to approximately 8.0 mm in diameter. Treatments were: group 1, saline injected as control; group 2, LH; group 3, rhuIL-2; or group 4, LH combined with rhuIL-2. LH utilized hot water circulation by a Brann Thermomix 1420. The intratumor temperature was maintained at 43 ± 0.2°C for 30 min each on days 6 and 10 and rhuIL-2 was given s.c. at 5 × 104 units twice a day for 5 days. Thirty mice in each group were sacrificed 28 days after tumor inoculation. An additional 20 mice in each group were observed for survival time. The size of primary tumor and the number of lung metastases were reduced and the survival time was prolonged in mice treated by either LH or IL-2. However, a greater antitumor effect in Lewis lung carcinoma tumor-bearing mice was observed using IL-2 therapy combined with LH. Tumor growth was associated with increased splenic granulocyte-macrophage progenitor cells and an abnormal L3T4+/Lyt-2+ lymphocyte subset ratio (<1.0). Splenic granulocyte-macrophage progenitor cell numbers and the L3T4+/Lyt-2+ ratio returned to normal in the group treated with combination therapy, the best responder group. The L3T4+/Lyt-2+ ratio did not change in the groups treated with single therapy. These results suggest the efficacy and possible clinical relevance of combined therapy with rhuIL-2 and LH for certain metastatic tumors.

UR - http://www.scopus.com/inward/record.url?scp=0025182212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025182212&partnerID=8YFLogxK

M3 - Article

C2 - 2379168

AN - SCOPUS:0025182212

VL - 50

SP - 5027

EP - 5030

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 16

ER -